Gilead Sciences (GILD) Given a $88.00 Price Target by Mizuho Analysts

Share on StockTwits

Gilead Sciences (NASDAQ:GILD) has been given a $88.00 price objective by investment analysts at Mizuho in a research report issued to clients and investors on Monday, TipRanks reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s price objective indicates a potential upside of 37.20% from the company’s previous close.

The analysts wrote, “DERM is a leading dermatology company with commercial and pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $25.””

Several other research analysts have also recently weighed in on GILD. Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, December 31st. Oppenheimer upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Thursday, January 3rd. CIBC upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $85.00 price target on the stock in a report on Thursday, January 3rd. Citigroup restated a “buy” rating and set a $100.00 price target on shares of Gilead Sciences in a report on Tuesday, February 5th. Finally, Wells Fargo & Co cut their price target on shares of Gilead Sciences from $95.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, February 5th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the company. Gilead Sciences has a consensus rating of “Buy” and an average price target of $80.94.

NASDAQ:GILD opened at $64.14 on Monday. The company has a quick ratio of 3.30, a current ratio of 3.38 and a debt-to-equity ratio of 1.19. The stock has a market cap of $80.37 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of 4.15 and a beta of 1.16. Gilead Sciences has a one year low of $60.32 and a one year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The company’s revenue was down 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.78 earnings per share. On average, equities analysts predict that Gilead Sciences will post 6.3 earnings per share for the current fiscal year.

In other Gilead Sciences news, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction dated Wednesday, April 10th. The shares were sold at an average price of $67.23, for a total value of $181,521.00. Following the transaction, the director now directly owns 57,560 shares in the company, valued at $3,869,758.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $65.48, for a total transaction of $624,286.32. Following the completion of the transaction, the director now owns 34,669 shares in the company, valued at $2,270,126.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 44,802 shares of company stock worth $2,956,422. Corporate insiders own 0.20% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp lifted its stake in shares of Gilead Sciences by 95.7% during the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock valued at $34,658,000 after buying an additional 271,000 shares in the last quarter. Chilton Capital Management LLC lifted its stake in shares of Gilead Sciences by 3.5% during the 4th quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock valued at $1,030,000 after buying an additional 555 shares in the last quarter. Nicholas Company Inc. lifted its stake in shares of Gilead Sciences by 2.7% during the 4th quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock valued at $31,697,000 after buying an additional 13,500 shares in the last quarter. Sectoral Asset Management Inc lifted its stake in shares of Gilead Sciences by 59.6% during the 4th quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock valued at $26,577,000 after buying an additional 158,750 shares in the last quarter. Finally, AIMZ Investment Advisors LLC lifted its stake in shares of Gilead Sciences by 39.9% during the 4th quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock valued at $3,361,000 after buying an additional 15,333 shares in the last quarter. Hedge funds and other institutional investors own 80.21% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Article: What are gap-down stocks?

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.